Ebos Group Limited · NZX:EBO
Ebos — Shareholder Meeting (October 2019)
25 slides from Ebos's shareholder meeting presentation, Oct 15, 2019
Slide 1: 97th Annual Meeting
For personal use only 97TH ANNUAL MEETING 15 October 2019
Slide 2: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability of For personal us
Slide 3: 2019 Annual Meeting - Chairman Mark Waller
For personal use only 2019 Annual Meeting Chairman – Mr Mark Waller
Slide 4: Agenda
AGENDA For personal use only Welcome Introducing members of the Board Presentations Mark Waller, Chairman John Cullity, Chief Executive Officer Business of meeting Conclusion 4
Slide 5: Board of Directors
BOARD OF DIRECTORS For personal use only Mark Waller Elizabeth Coutts Independent Chair of Independent Chair Elect of Directors Directors Appointed 1987 Joined 2003 Appointed Chair 2015 Retiring October 2019 Stuart McGregor Sarah Ottrey Peter Williams Stuart Non-executive Independent Non-executive M
Slide 6: Retirement of Mark Waller, Appointment of Liz Coutts as New Chair
RETIREMENT OF MARK WALLER APPOINTMENT OF LIZ COUTTS AS NEW CHAIR For personal use only Mr Mark Waller will retire as a Director and Chairman of EBOS Group Limited, effective from 15 October 2019. The Board has elected Liz Coutts as Chair with effect from Mr Waller’s retirement. Ms Coutts has bee
Slide 7: FY19 Summary Results
FY19 SUMMARY RESULTS For personal use only FY19 Underlying A$m Statutory Underlying2 FY18 Var Var% Revenue 6,930.4 6,930.4 6,986.7 (56.4) (0.8%) EBITDA 250.4 261.6 250.1 11.6 4.6% NPAT1 137.7 144.4 137.3 7.2 5.2% Earnings per Share (cents) 89.8c 94.2c 90.4c 3.8 4.3% Total Dividends (cents) 71.5c 71.
Slide 8: Strategic Investments Are Driving Shareholder Returns
STRATEGIC INVESTMENTS ARE DRIVING SHAREHOLDER RETURNS For personal use only $600m invested over the last five years 188.7 30.8 93.6 56.8 84.1 58.0 35.5 26.6 13.7 11.5 FY15 FY16 FY17 FY18 FY19 Capital expenditure Acquisitions and investments 8
Slide 9: NZ$175M Successful Capital Raising to Continue Our Growth Strategy
NZ$175M SUCESSFUL CAPITAL RAISING TO CONTINUE OUR GROWTH STRATEGY For personal use only For over 34 years the Group has delivered long term sustainable returns for all Shareholders through our strategy of investing for growth and productivity. This has delivered Total Shareholder annualised Returns
Slide 10: 2019 Annual Meeting - CEO John Cullity
For personal use only 2019 Annual Meeting CEO – Mr John Cullity
Slide 11: Corporate Video
CORPORATE VIDEO The corporate video that will be shown at the Annual Meeting can For personal use only be viewed on the EBOS Group website at www.ebosgroup.com 11
Slide 12: Investment Strategy Has Delivered Strong Growth in EBITDA and EPS
OUR INVESTMENT STRATEGY HAS DELIVERED STRONG GROWTH IN EBITDA AND EPS OVER THE LAST 5 YEARS For personal use only 5 Year Underlying EBITDA 5 Year Underlying EPS Underlying EBITDA – FY15 A$m to FY19 (A$m) Underlying EPS – FY15 to FY19 cents per share (A$m) FY19 261.6 FY19 94.2 FY18 250.1 FY18 90.4 5
Slide 13: FY19 Strategic Highlights
FY19 STRATEGIC HIGHLIGHTS Acquisitions of $93.6m Two major facilities opened in Australia For personal use only Acquisition of all the minority shares in Brisbane - new highly automated wholesale distribution TerryWhite Group Ltd for $46.7m in centre commenced operations in October 2018. Decembe
Slide 14: FY20 Acquisition into Medical Devices Market Creates New Growth Platform
FY20 ACQUISITION INTO MEDICAL DEVICES MARKET CREATES NEW GROWTH PLATFORM For personal use only We are pleased to announce the Group’s entry into the A$8 billion Australian and New Zealand medical device sector, with the strategic acquisition of established distribution business LMT and National Su
Slide 15: FY19 Segment Performance: Healthcare
FY19 SEGMENT PERFORMANCE HEALTHCARE For personal use only Australia revenue down 3.5% (or up 5.2% excluding A$m FY19 FY18 Var$ Var% hepatitis C medicine sales and PBS price reforms1). Revenue 6,548.3 6,608.6 (60.3) (0.9%) Underlying EBITDA up 5.7% primarily from growth in Institutional Healthcare
Slide 16: FY19 Segment Performance: Animal Care
FY19 SEGMENT PERFORMANCE ANIMAL CARE For personal use only EBITDA increase of $2.6m or 5.7%: A$m FY19 FY18 Var$ Var% Revenue 382.0 378.2 3.9 1.0% Earnings improvement is primarily from Black Hawk sales revenue growth of 11.4%. EBITDA 48.3 45.7 2.6 5.7% Total EBITDA margin improvement again refle
Slide 17: Employee and Social Responsibility
EMPLOYEE AND SOCIAL RESPONSIBILITY EBOS Group is committed to employee and social responsibility across Australia and New Zealand. For personal use only Employee Health, safety Employee ECHO Program EMPLOYEES engagement and Assistance (Environment, survey. wellbeing. Program Community, (EAP)
Slide 18: FY20 Trading Update
FY20 TRADING UPDATE For personal use only Trading for the first quarter of FY20 is in line with our internal expectations and we reconfirm the Group is confident of a significant increase in earnings in the current financial year. 18
Slide 19: Business of Meeting
For personal use only 2019 Annual Meeting Business of Meeting
Slide 20: Item: Amendment of Constitution
ITEM 1 Amendment of Constitution For personal use only It is hereby resolved to amend the constitution of the Company in the manner described in the explanatory notes with effect from the time the resolution is passed. 20
Slide 21: Item: Annual Report and Financial Statements
ITEM 2 Annual Report and Financial Statements For personal use only To consider and receive the Annual Report and the Financial Statements for the year ended 30 June 2019 and the audit report thereon. 21
Slide 22: Item: Election of Director
ITEM 3 Election of Director For personal use only It is hereby resolved that Mr Stuart McLauchlan be elected as a Director of the Company. Stuart was appointed to the EBOS Group Limited Board in July 2019. Stuart is a Chartered Fellow of the Institute of Directors and a Past President. He is a cha
Slide 23: Item: Non-executive directors' remuneration
ITEM 4 Non-executive directors’ remuneration For personal use only It is hereby resolved that, pursuant to NZX Listing Rule 2.11.1 and ASX Listing Rule 10.17, total annual remuneration for Non-Executive Directors be increased by $310,000 from $1,100,000 to $1,410,000 with effect from 1 July 2019.
Slide 24: Item: Auditor's Remuneration
ITEM 5 Auditor’s Remuneration For personal use only It is hereby resolved that the Directors of the Company be authorised to fix the fees and expenses of Deloitte as auditor of the Company. 24
Slide 25: Thank you for attending
Thank you for attending For personal use only Please join us for refreshments www.ebosgroup.com